Results 1 to 10 of about 334,676 (308)

High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014

Infection and Drug Resistance, 2017
Hung-Chin Tsai,1–3 I-Tzu Chen,1 Kuan-Sheng Wu,1,2 Yu-Ting Tseng,1 Cheng-Len Sy,1 Jui-Kuang Chen,1 Susan Shin-Jung Lee,1,2 Yao-Shen Chen1,2 1Department of Medicine, Division of Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung ...
Tsai HC, Chen IT, Wu KS, Tseng YT, Sy CL, Chen JK, Lee SS, Chen YS   +7 more
doaj   +1 more source

Drug Resistance Predictions Based on a Directed Flag Transformer

Advanced Science
The evolving SARS‐CoV‐2 virus threatens global public health, particularly with potential resistance to PAXLOVID, whose active ingredient, nirmatrelvir, targets the viral main protease (Mpro).
Dong Chen, Gengzhuo Liu, Hongyan Du, Benjamin Jones, Junjie Wee, Rui Wang, Jiahui Chen, Jana Shen, Guo‐Wei Wei   +8 more
doaj   +1 more source

HIV-1 drug resistance-associated mutations in relation to viral load among HIV/AIDS patients at Dr. M. Djamil-Hospital Padang

Universa Medicina
Background According to the WHO, 38 million people suffer from HIV worldwide and according to the HIV Drug Resistance Report, the prevalence of antiretroviral therapy (ART) resistance is 3-29%.
Rizka Nadia, Dwitya Elvira, Raveinal Raveinal   +2 more
doaj   +1 more source

Resistant Mutations Against Nucleot(s)ide Analogues (NAs) in RT Domain of HBV Genome: A Review

Viral Hepatitis Journal
Drug resistance is a significant hurdle in the control and treatment of chronic hepatitis B virus (HBV) infection. This resistance is caused by some mutations in the viral genome which enable alternative ways for viral replication; which otherwise is ...
Zia Ur Rahman, Majid Mahmood
doaj   +1 more source

HIV transmission dynamics and population-wide drug resistance in rural South Africa

Nature Communications
Despite expanded antiretroviral therapy (ART) in South Africa, HIV-1 transmission persists. Integrase strand transfer inhibitors (INSTI) and long-acting injectables offer potential for superior viral suppression, but pre-existing drug resistance could ...
Steven A. Kemp, Kimia Kamelian, Diego F. Cuadros, PANGEA Consortium, Vukuzazi Team, Mark T. K. Cheng, Elphas Okango, Willem Hanekom, Thumbi Ndung’u, Deenan Pillay, David Bonsall, Emily B. Wong, Frank Tanser, Mark J. Siedner, Ravindra K. Gupta   +14 more
doaj   +1 more source

Integrating haplotype-enhanced HIV surveillance with national databases improves the resolution of transmission networks, drug resistance, and risk assessment. [PDF]

Emerg Microbes Infect
Cai D, Feng Y, Gan M, Li H, Wang D, Hao J, Lin L, Tang Y, Wang Y, Liao L, Wang Z, Xing H.   +11 more
europepmc   +1 more source

Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1. [PDF]

PLoS Pathog
Jaki L, Full F, Gieraths U, Falcone V, Ruzsics Z, Hengel H, Panning M, Fuchs J.   +7 more
europepmc   +1 more source

Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir. [PDF]

Front Public Health
Perno CF, Orlando S, Majid NA, Sangare H, Luanga R, Roccucci M, Silaghi LA, Sidumo Z, Brambilla D, Ceffa S, Guidotti G, Ciccacci F.   +11 more
europepmc   +1 more source

Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections. [PDF]

Virol J
Petakh P, Ravlo E, Pan Q, Bruzzone R, Oksenych V, Vähä-Koskela M, Kamyshnyi O, Kainov DE.   +7 more
europepmc   +1 more source

Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failure. [PDF]

PLoS Pathog
Pillay M, Choudhary MC, Deo R, Naumenko S, Tamura TJ, Etemad B, Edelstein G, Khan A, Govender K, Govender S, Tzou P, Mick M, Herbert ZT, Muyindike W, Moosa MS, Brijkumar J, Sunpath H, McCluskey S, Chimukangara B, Manyana SC, Gounder L, Parboosing R, Francois KL, Shafer R, Ho Sui S, Pillay S, Marconi V, Siedner MJ, Moodley P, Msomi N, Li JZ.   +30 more
europepmc   +1 more source